In September 2020, MindMed announced their application to list on the Nasdaq. Speaking to Psilocybin Alpha, CEO and Co-founder JR Rahn explained his hopes that the move would give the company further access to U.S. capital markets, hot on the heels of COMPASS Pathways’ $146.6m IPO. Today, the company fulfills that ambition, listing on the Nasdaq under ticker symbol MNMD. As such…
